Literature DB >> 19883275

Reproductive wish represents an important factor influencing therapeutic strategy in inflammatory bowel diseases.

Zuzana Zelinkova1, Peter B F Mensink, Jan Dees, Ernst J Kuipers, Christien J van der Woude.   

Abstract

OBJECTIVE: Inflammatory bowel disease (IBD) affects patients in reproductive age but little is known about the peri-conceptional use of medication for IBD. The aim of this study was to assess the type of medication used by IBD patients with the desire to reproduce and changes in medication in the peri-conceptional period.
MATERIAL AND METHODS: IBD patients with active conception plans and pregnant patients were prospectively recruited from the outpatient clinic of a single academic medical center. IBD-related medication and changes in this medication for reasons of a desire to conceive or pregnancy were analyzed.
RESULTS: In total, 61 patients (51 females; 40 with Crohn's disease, 21 with ulcerative colitis) were included. Thirteen patients (21%) used no medication, 44 (72%) used monotherapy and four (7%) used combination treatment. Of patients on monotherapy, 11 (19%) used 5-aminosalicylates, five (9%) used steroids, 11 (19%) used thiopurines, five (9%) used methotrexate and 11 (19%) used anti-tumor necrosis factor agents. Thirty-seven patients (61%) consulted a physician prior to conception. About one-third of these patients required a change in their medication due to their conception plans.
CONCLUSIONS: In a referral center, the majority of IBD patients with conception plans require medication for which limited information on the safety of peri-conceptional use is available. In addition, the desire to reproduce leads to medication changes in about one-third of these patients.

Entities:  

Mesh:

Year:  2010        PMID: 19883275     DOI: 10.3109/00365520903362628

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  6 in total

Review 1.  Reproductive Planning and Contraception for Women with Inflammatory Bowel Diseases.

Authors:  Lori M Gawron; Jessica Sanders; Katelyn P Steele; Ann D Flynn
Journal:  Inflamm Bowel Dis       Date:  2016-02       Impact factor: 5.325

Review 2.  Managing IBD Therapies in Pregnancy.

Authors:  Jill K J Gaidos; Sunanda V Kane
Journal:  Curr Treat Options Gastroenterol       Date:  2017-03

Review 3.  Contraceptive Considerations for Women with Gastrointestinal Disorders.

Authors:  Aparna Sridhar; Carrie A Cwiak; Andrew M Kaunitz; Rebecca H Allen
Journal:  Dig Dis Sci       Date:  2016-11-24       Impact factor: 3.199

4.  Management of Inflammatory Bowel Disease in Pregnancy: A Practical Approach to New Guidelines.

Authors:  V Huang; Y Leung; G C Nguyen; C H Seow
Journal:  Can J Gastroenterol Hepatol       Date:  2016-07-11

5.  Management of Inflammatory Bowel Disease during Pregnancy and Breastfeeding Varies Widely: A Need for Further Education.

Authors:  Vivian Wai-Mei Huang; Hsiu-Ju Chang; Karen Ivy Kroeker; Karen Jean Goodman; Kathleen M Hegadoren; Levinus Albert Dieleman; Richard Neil Fedorak
Journal:  Can J Gastroenterol Hepatol       Date:  2016-09-20

6.  Reproductive Health and Medication Concerns for Patients With Inflammatory Bowel Disease: Thematic and Quantitative Analysis Using Social Listening.

Authors:  Michelle Sophie Keller; Sasan Mosadeghi; Erica R Cohen; James Kwan; Brennan Mason Ross Spiegel
Journal:  J Med Internet Res       Date:  2018-06-11       Impact factor: 5.428

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.